 |
|
|
|
 |
|
|
| Article 1 to 10 out of 22 concerning Merck KGaA
|
-
OncoMethylome Sciences Announces Licensing and Testing Agreement with Merck KGaA
(06/11/2008)
OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide
OncoMethylome Sciences announced that it has signed a licensing and testing agreement with Merck KGaA of Darmstadt, Germany. Under the terms of the agreement, OncoMethylome will provide MGMT gene promoter methylation testing services for Merck's ...
-
caprotec bioanalytics and Merck KGaA Sign Collaboration Agreement
(05/30/2008)
caprotec bioanalytics GmbH announced that they have signed a collaboration agreement with Merck KGaA acting for its division Merck Serono. Under the terms of the agreement caprotec will apply its Capture Compound Mass Spectrometry(TM) (CCMS) ...
-
Oncothyreon to receive milestone payment from Merck KGaA
(05/16/2008)
Oncothyreon Inc. announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany, triggering a payment to Oncothyreon of $3 million. The ...
-
BIOTECON Diagnostics and Merck KGaA start worldwide marketing alliance
(04/18/2008)
PCR-based detection kits for rapid food safety testing
In order to enhance the worldwide launch of its food safety testing systems, BIOTECON Diagnostics has formed a strategic marketing alliance with the globally operating Merck KGaA, Darmstadt, Germany. Merck KGaA sells the foodproof® range which has ...
-
Merck Announces Joint Agreement With ImClone and Bristol-Myers Squibb for Erbitux in Japan
(10/19/2007)
Co-development and co-commercialization of Erbitux in metastatic colorectal cancer upon health authority approval
Merck KGaA announced that it has established an agreement with ImClone Systems Incorporated and Bristol-Myers Squibb Company for the co-development and co-commercialization of Erbitux® (cetuximab) in Japan if approved by the Japanese Pharmaceuticals ...
-
Delisting of Merck Serono shares expected on July 18, 2007
(07/10/2007)
Squeeze Out Successfully Completed
The Civil Court of Basel has cancelled all remaining publicly held shares of Merck Serono S.A. (Merck Serono) and annulled all outstanding rights to acquire such shares. Therefore, Merck now holds 100% of the shares of Merck Serono. Merck Serono's ...
-
Genmab regains rights to HuMax-CD4
(07/03/2007)
Genmab A/S announced it has regained all rights to the HuMax-CD4® (zanolimumab) antibody from Merck Serono S.A. Genmab plans to continue moving development of HuMax-CD4 forward in the existing non-cutaneous T-cell lymphoma and cutaneous T-cell ...
-
AnalytiCon Discovery Announces Collaboration Agreement With Merck KGaA on Natural Product Lead Generation Program
(05/31/2007)
AnalytiCon Discovery GmbH and Merck KGaA have entered into an agreement whereby AnalytiCon will provide Merck with natural product lead generation services until the end of 2009.Under the agreement, AnalytiCon will apply its proprietary MEGAbolite® ...
-
DNT and EMD Biosciences sign siRNA and DNA reagent license and supply agreement
(02/21/2007)
Dendritic Nanotechnologies Inc (DNT), a Starpharma Holdings Company, has entered into a worldwide exclusive license and supply agreement with EMD Biosciences, part of Merck KGaA's Performance and Life Science Chemicals division.Under the terms of ...
-
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics
(01/19/2007)
Archemix Corp. announced that it has signed a multi-year, multi-target agreement with Merck KGaA, that focuses on the discovery, development, and commercialization of first-in-class aptamer-based therapeutics to treat cancer.Under terms of the ...
Additional information
Merck KGaA
Darmstadt, Germany
Company
Jobs
|
|
|
|
|
|
Top
